COVID-19 VaccinE Response in Rheumatology Patients

• Status: Not yet recruiting
• Trial end date: 2022-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The COVID-19 VaccinE Response in Rheumatology patients (COVER) study is a multicenter randomized controlled trial designed to evaluate the efficacy and safety of a mRNA COVID-19 vaccine supplemental dose (booster) in patients with autoimmune conditions and to evaluate the impact of different immunomodulatory therapies on vaccine response. The investigators propose to recruit up to 1000- patients with autoimmune conditions who have a completed 2-dose regime of mRNA COVID-19 vaccine (>28 days prior) and who are planning to receive an additional dose of mRNA COVID-19 vaccine (i.e., booster). Participants in this study will be men and women 18 years and older with confirmed rheumatic disease, including psoriatic arthritis (PsA), axial spondyloarthritis (SpA) and rheumatoid arthritis (RA) who express a decision to receive the mRNA vaccination booster within 30 days post enrollment.

A primary objective of this study is to test the hypothesis that holding certain medications for a brief period of time around the time of COVID-19 vaccination might improve the response to the vaccine while not unduly having safety concerns with respect to the effects of their disease. During the study, participants using the immunomodulatory therapies described outlined in protocol will be randomized to temporarily hold (for 2 weeks) versus continue after they receive the COVID-19 vaccine supplemental dose. Patients who temporarily stop one of their medications for their autoimmune inflammatory disease may be at increased risk of flares of their autoimmune condition. If these occur, they are expected to occur within 2 - 4 weeks of treatment interruption. Detailed protocol outlines the hold schedules for the therapies to be randomized in this study.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Jeffrey Curtis
• Collaborators: AbbVie; Bristol-Myers Squibb; Eli Lilly and Company; Novartis; Pfizer; University of Alabama at Birmingham; University of Nebraska; University of Pennsylvania
• Treatments: Abatacept; Adalimumab; Etanercept; Golimumab; Tofacitinib; Tumor Necrosis Factor Inhibitors; Upadacitinib

Criteria

Inclusion Criteria: *Patients must meet all of the inclusion criteria at the time of screening*

• Must have a rheumatology provider diagnosis of one or more of the following autoimmune inflammatory conditions:

• Rheumatoid arthritis or adults previously diagnosed with Juvenile idiopathic arthritis (analyzed as a single category)

• Psoriatic arthritis (PsA), Ankylosing spondylitis (ASp), or other Spondyloarthritis (SpA)

• Must have completed the 2-dose regimen of either of the two mRNA COVID-19 vaccines more than 28 days previous to enrollment

• Must be scheduled for an additional dose of mRNA COVID-19 vaccination booster (or with plans to schedule booster) within the next 30 days

• Must have a cell phone capable of receiving text messages, and/or a personal email address

• Currently receiving one of the medications described in Table 1

• Without any meaningful interruption or change in immunomodulatory therapy since the time of initial vaccine series to the time of study enrollment. Dose changes of immunomodulatory therapies are permitted, as are brief interruptions of < 2 weeks

• Must be 18 years of age or older

• Must live in the United States.

Exclusion Criteria:

• • Already received a non-mRNA COVID-19 vaccine dose (J&J)

• Any use in the past 90 days of a monoclonal antibody against COVID-19 (e.g., bamlanivimab, casirivimab, imdevimab)

• Any known contraindication to COVID-19 vaccination, including allergic reaction to prior COVID-19 vaccination, and severe allergy to vaccine components (e.g., pegloticase)

• Known HIV/AIDS or any other immunodeficient condition

• Use of immunomodulatory therapy for any non-rheumatologic indication (e.g., organ transplantation)

• Currently receiving radiation or chemotherapy for any type of malignancy.

• Receipt of any immunization other than COVID-19 within two weeks prior to the COVID-19 vaccine supplemental dose

• Significant underlying illness that would be expected to prevent completion of the study (e.g., life-threatening disease likely to limit survival to < 1 year)

• Any other reason that, in the opinion of the site investigator, would interfere with required study related evaluations (e.g., uncontrolled disease flare, uncontrolled comorbidity)